CHINARES PHARMA (03320) Leads Establishment of RMB 500 Million Fund, Focusing on Synthetic Biology and Innovative Drugs

Stock News

Oct 30

CHINARES PHARMA (03320) announced that on October 29, 2025, CHINARES PHARMA (Shantou) (as the general partner), CHINARES DOUBLE-CRANE (as the limited partner), and CHINARES PHARMA Investment (as the limited partner) (each being a subsidiary of the company), along with other partners, entered into a limited partnership agreement to establish a proposed fund with a scale of RMB 500 million. The fund will primarily invest in high-growth enterprises in the fields of synthetic biology, innovative drugs, and biotechnology. The group intends to commit a total of RMB 123 million, accounting for approximately 24.6% of the fund's total committed capital. Upon establishment, the fund will not be consolidated as a subsidiary of the company. Shenzhen CHINARES Capital has been appointed as the fund manager. Synthetic biology is one of the group's strategic development directions. By establishing the fund, the group aims to build an industrial platform for synthetic biology in Hohhot, optimizing its strategic layout in key related sectors. Additionally, leveraging Hohhot's industrial synergies, the group expects the fund to achieve objectives such as diversifying synthetic biology investment channels, fostering innovation incubation, accelerating product and technology collaborations, and securing commercialization rights. After its establishment, the fund will be recorded as an equity investment in the company's consolidated financial statements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1102883267"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1102883267\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1102883267?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 08:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102883267","market":"hk","top_or_hot":-1,"title":"CHINARES PHARMA (03320) Leads Establishment of RMB 500 Million Fund, Focusing on Synthetic Biology and Innovative Drugs","media":"Stock News","content":"<p>CHINARES PHARMA (03320) announced that on October 29, 2025, CHINARES PHARMA (Shantou) (as the general partner), CHINARES DOUBLE-CRANE (as the limited partner), and CHINARES PHARMA Investment (as the limited partner) (each being a subsidiary of the company), along with other partners, entered into a limited partnership agreement to establish a proposed fund with a scale of RMB 500 million. The fund will primarily invest in high-growth enterprises in the fields of synthetic biology, innovative drugs, and biotechnology. The group intends to commit a total of RMB 123 million, accounting for approximately 24.6% of the fund's total committed capital. Upon establishment, the fund will not be consolidated as a subsidiary of the company. Shenzhen CHINARES Capital has been appointed as the fund manager. Synthetic biology is one of the group's strategic development directions. By establishing the fund, the group aims to build an industrial platform for synthetic biology in Hohhot, optimizing its strategic layout in key related sectors. Additionally, leveraging Hohhot's industrial synergies, the group expects the fund to achieve objectives such as diversifying synthetic biology investment channels, fostering innovation incubation, accelerating product and technology collaborations, and securing commercialization rights. After its establishment, the fund will be recorded as an equity investment in the company's consolidated financial statements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CHINARES PHARMA (03320) Leads Establishment of RMB 500 Million Fund, Focusing on Synthetic Biology and Innovative Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCHINARES PHARMA (03320) Leads Establishment of RMB 500 Million Fund, Focusing on Synthetic Biology and Innovative Drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-30 08:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CHINARES PHARMA (03320) announced that on October 29, 2025, CHINARES PHARMA (Shantou) (as the general partner), CHINARES DOUBLE-CRANE (as the limited partner), and CHINARES PHARMA Investment (as the limited partner) (each being a subsidiary of the company), along with other partners, entered into a limited partnership agreement to establish a proposed fund with a scale of RMB 500 million. The fund will primarily invest in high-growth enterprises in the fields of synthetic biology, innovative drugs, and biotechnology. The group intends to commit a total of RMB 123 million, accounting for approximately 24.6% of the fund's total committed capital. Upon establishment, the fund will not be consolidated as a subsidiary of the company. Shenzhen CHINARES Capital has been appointed as the fund manager. Synthetic biology is one of the group's strategic development directions. By establishing the fund, the group aims to build an industrial platform for synthetic biology in Hohhot, optimizing its strategic layout in key related sectors. Additionally, leveraging Hohhot's industrial synergies, the group expects the fund to achieve objectives such as diversifying synthetic biology investment channels, fostering innovation incubation, accelerating product and technology collaborations, and securing commercialization rights. After its establishment, the fund will be recorded as an equity investment in the company's consolidated financial statements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1102883267","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102883267","pubTimestamp":1761782773,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CHINARES PHARMA (03320) announced that on October 29, 2025, CHINARES PHARMA (Shantou) (as the general partner), CHINARES DOUBLE-CRANE (as the limited partner), and CHINARES PHARMA Investment (as the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","BK1191":"制药","BK1161":"生物科技","BK1570":"华润系","BK1574":"生物医药B类股","06978":"永泰生物-B","03320":"华润医药"},"translate_title":"CHINARES PHARMA(03320)牵头成立5亿元基金专注合成生物及创新药","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"03320":1,"06978":1},"content_text":"CHINARES PHARMA (03320) announced that on October 29, 2025, CHINARES PHARMA (Shantou) (as the general partner), CHINARES DOUBLE-CRANE (as the limited partner), and CHINARES PHARMA Investment (as the limited partner) (each being a subsidiary of the company), along with other partners, entered into a limited partnership agreement to establish a proposed fund with a scale of RMB 500 million. The fund will primarily invest in high-growth enterprises in the fields of synthetic biology, innovative drugs, and biotechnology. The group intends to commit a total of RMB 123 million, accounting for approximately 24.6% of the fund's total committed capital. Upon establishment, the fund will not be consolidated as a subsidiary of the company. Shenzhen CHINARES Capital has been appointed as the fund manager. Synthetic biology is one of the group's strategic development directions. By establishing the fund, the group aims to build an industrial platform for synthetic biology in Hohhot, optimizing its strategic layout in key related sectors. Additionally, leveraging Hohhot's industrial synergies, the group expects the fund to achieve objectives such as diversifying synthetic biology investment channels, fostering innovation incubation, accelerating product and technology collaborations, and securing commercialization rights. After its establishment, the fund will be recorded as an equity investment in the company's consolidated financial statements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}